Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) announced the commencement of a proposed underwritten public offering of $500,000,000 of common stock and pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $75,000,000.
The offering is subject to market and other conditions; a shelf registration was automatically effective May 24, 2024, and a preliminary prospectus supplement will be filed with the SEC.
Positive
- Potential capital raise of $500,000,000
- Underwriter option to increase size by $75,000,000
- Shelf registration effective May 24, 2024
Negative
- Creates potential shareholder dilution from offered shares and pre-funded warrants
- Completion is uncertain and dependent on market and other conditions
- Pre-funded warrants increase future share issuance risk if exercised
News Market Reaction – PCVX
In the Jan 30 session, PCVX gained 1.42%, reflecting a mild positive market reaction. Argus tracked a peak move of +16.1% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 06 | Offering closing | Negative | +3.3% | Closed large public offering with full underwriters’ option exercise. |
| Sep 04 | Offering pricing | Negative | +2.7% | Priced $1.3B public offering of common stock and pre-funded warrants. |
| Sep 03 | Offering commencement | Negative | -0.9% | Announced start of $1.0B underwritten public offering and 30-day option. |
| Feb 02 | Offering closing | Negative | -1.5% | Closed $862.5M public offering including full underwriters’ option. |
| Jan 30 | Offering pricing | Negative | +6.0% | Announced pricing of $750M public offering of common stock. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings often saw mixed reactions, with several instances of positive price moves despite typically dilutive headlines.
Over the past two years, PCVX has repeatedly tapped equity markets via underwritten offerings and related transactions. Prior offering announcements in Jan 2024, Feb 2024 and early Sep 2024 covered pricing, commencement and closings, including a notable $1.5 billion raise with full underwriter option exercise. Price reactions ranged from modest declines to gains above 6%, indicating investors sometimes viewed these financings constructively. Today’s proposed offering continues this pattern of sizable equity raises to support the company’s vaccine programs.
Key Terms
underwritten public offering financial
pre-funded warrants financial
book-running managers financial
shelf registration statement regulatory
prospectus supplement regulatory
Securities and Exchange Commission (SEC) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of
BofA Securities, Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Department, 520 Madison Avenue, New York, New York 10022, by telephone at 1-877-821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6105; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200 or by email at ecm.prospectus@evercore.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
